OpenNashEarnings

Pharmaceuticals · Nasdaq: GILD

Gilead Sciences earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 9 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Gilead's third quarter 2026 product sales excluding Veklury increased 16% year-over-year to $8.2 billion and Biktarvy sales increased 10% to $4.1 billion, with diluted EPS of $1.94 and non-GAAP diluted EPS of $2.55.

Gilead's base business, meaning product sales excluding Veklury, grew 16% to $8.2 billion, its strongest growth in more than a decade. HIV sales rose 18% to $6.2 billion, helped by higher prices, rising demand for HIV prevention and favorable inventory timing. Trodelvy grew 42% and Livdelzi nearly doubled. GAAP diluted EPS fell to $1.94 from $2.43 because of equity-security losses, higher expenses and lower royalty revenue. Non-GAAP EPS rose to $2.55 from $2.47.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$8.3B+6.8% y/yQ3 2026
Q4 2024: $7.6B (worked out from the annual figure)Q4 ’24$7.6BQ1 2025: $6.7BQ1 ’25$6.7BQ2 2025: $7.1BQ2 ’25$7.1BQ3 2025: $7.8BQ3 ’25$7.8BQ4 2025: $7.9B (worked out from the annual figure)Q4 ’25$7.9BQ1 2026: $7.0BQ1 ’26$7.0BQ2 2026: $7.8BQ2 ’26$7.8BQ3 2026: $8.3BQ3 ’26$8.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$7.6B *
Q1 2025$6.7B
Q2 2025$7.1B
Q3 2025$7.8B
Q4 2025$7.9B *
Q1 2026$7.0B
Q2 2026$7.8B
Q3 2026$8.3B
Diluted EPS (GAAP)$1.94−20.2% y/yQ3 2026
Q1 2025: $1.04Q1 ’25$1.04Q2 2025: $1.56Q2 ’25$1.56Q3 2025: $2.43Q3 ’25$2.43Q1 2026: $1.61Q1 ’26$1.61Q2 2026: -$8.45Q2 ’26-$8.45Q3 2026: $1.94Q3 ’26$1.94
Data
Q1 2025$1.04
Q2 2025$1.56
Q3 2025$2.43
Q1 2026$1.61
Q2 2026-$8.45
Q3 2026$1.94

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin41.7%−1.1 pts y/yQ3 2026
Q4 2024: 32.4%Q4 ’2432.4%Q1 2025: 33.6%Q1 ’2533.6%Q2 2025: 34.9%Q2 ’2534.9%Q3 2025: 42.8%Q3 ’2542.8%Q4 2025: 25.0%Q4 ’2525.0%Q1 2026: 37.2%Q1 ’2637.2%Q2 2026: -133.2%Q2 ’26-133.2%Q3 2026: 41.7%Q3 ’2641.7%
Data
Q4 202432.4%
Q1 202533.6%
Q2 202534.9%
Q3 202542.8%
Q4 202525.0%
Q1 202637.2%
Q2 2026-133.2%
Q3 202641.7%
Free cash flow$4.8B+21.1% y/yQ3 2026
Q4 2024: $2.8BQ4 ’24$2.8BQ1 2025: $1.7BQ1 ’25$1.7BQ2 2025: $720.0MQ2 ’25$720.0MQ3 2025: $4.0BQ3 ’25$4.0BQ4 2025: $3.1BQ4 ’25$3.1BQ1 2026: $2.4BQ1 ’26$2.4BQ2 2026: $3.4BQ2 ’26$3.4BQ3 2026: $4.8BQ3 ’26$4.8B
Data
Q4 2024$2.8B
Q1 2025$1.7B
Q2 2025$720.0M
Q3 2025$4.0B
Q4 2025$3.1B
Q1 2026$2.4B
Q2 2026$3.4B
Q3 2026$4.8B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$7.6Bd$6.7B$7.1B$7.8B$7.9Bd$7.0B$7.8B$8.3B
Operating income$2.5Bd$2.2B$2.5B$3.3B$2.0Bd$2.6B-$10.4B$3.5B
Operating margin32.4%33.6%34.9%42.8%25.0%37.2%-133.2%41.7%
Net income$1.8Bd$1.3B$2.0B$3.1B$2.2Bd$2.0B-$10.5B$2.4B
Diluted EPS—$1.04$1.56$2.43—$1.61-$8.45$1.94
Operating cash flow$3.0Bd$1.8B$827.0Md$4.1Bd$3.3Bd$2.5B$3.6Bd$5.0Bd
Capital expenditure$147.0Md$104.0M$107.0Md$147.0Md$205.0Md$117.0M$140.0Md$237.0Md
Free cash flow$2.8B$1.7B$720.0M$4.0B$3.1B$2.4B$3.4B$4.8B
R&D expense$1.6Bd$1.4B$1.5B$1.3B$1.6Bd$1.4B$1.8B$1.6B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-Q and 10-K filings